Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship?
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
pubmed:
3
8
2021
medline:
3
9
2021
entrez:
2
8
2021
Statut:
ppublish
Résumé
Anaphylactic reactions reported after Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) RNA vaccines were expected to be more frequent in atopic subjects and attributed to its polyethylene glycol component. Anaphylaxis to SARS-CoV2 RNA vaccines is no more frequent than in any vaccine and direct proofs for the role of its polyethylene glycol component are lacking. Vaccines against coronavirus disease 2019 (COVID-19) are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have rapidly been reported after SARS-CoV2 RNA vaccines. This risk is now measured at 2.5-11/1 000 000 in the context of vaccine safety surveillance programs and only one case was documented to be due to polyethylene glycol. Suggestions for its role are indirect. The COVID-19 vaccination is rolling out vastly and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care, highlighting the key role of allergists in the vaccination programmes.
Identifiants
pubmed: 34334663
doi: 10.1097/ACI.0000000000000778
pii: 00130832-202110000-00002
doi:
Substances chimiques
COVID-19 Vaccines
0
Polyethylene Glycols
3WJQ0SDW1A
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
411-417Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
World Health Organization website. Available at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-april-2021 . [Assessed April 2021]
Centers of Disease Control website. Available at: https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm . [Assessed April 2021]
Pfizer and BioNTech achieve first authorization in the world for a vaccine to combat COVID-19. 2020. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-achieve-first-authorization-world . [Accessed 14 January 2021]
U.S. FDA takes additional action in fight against COVID-19 by issuing emergency use authorization for second COVID-19 vaccine. 2020. Available at: https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid . [Accessed 14 January 2021]
Moderna. Press Release. 2021. Available at: https://investors.modernatx.com/news-releases . [Accessed 22 January 2021]
AstraZeneca's COVID-19 vaccine authorized for emergency supply in the UK. 2020. Available at: https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html . [Accessed 14 January 2021]
Sellaturay P, Nasser S, Islam S, et al. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin Exp Allergy 2021.
Raine J. Medicines and Healthcare products Regulatory Agency (MHRA). Confirmation of guidance to vaccination centres on managing allergic reactions following COVID-19 vaccination with the Pfizer/BioNTech vaccine. Available at: https://www.gov.uk/government/news/confirmation-of-guidance-to-vaccination-centres-on-managing-allergic-reactions-following-covid-19-vaccination-with-the-pfizer-biontech-vaccine press release. [Accessed 9 December 2020]
Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States – Appendix B. United States Centers for Disease Control and Prevention; Atlanta, GA. 2020. Available at: cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html. [Accessed 20 December 2020]
Turner PJ, Ansotegui IJ, Campbell DE, et al., WAO Anaphylaxis Committee. COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J 2021; 14:100517doi: 10.1016/j.waojou.2021.100517.
doi: 10.1016/j.waojou.2021.100517
Tanno LK, Berard F, Beaudoin E, et al., on behalf of the Montpellier WHO Collaborating Centre and French Allergy Society. SARS-CoV-2 vaccination & anaphylaxis: recommendations of the French Allergy Community & the Montpellier World Health Organization Collaborating Centre. Vaccines 2021; in press.
Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and approach. J Allergy Clin Immunol Pract 2020; doi: 10.1016/j.jaip.2020.12.047.
doi: 10.1016/j.jaip.2020.12.047
Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J 2020; 13:100472.
Panesar SS, Javad S, de Silva D, et al., EAACI Food Allergy and Anaphylaxis Group. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy 2013; 68:1353–1361.
Tanno LK, Molinari N, Bruel S, et al., Joint Allergy Academies. Field-testing the new anaphylaxis’ classification for the WHO International Classification of Diseases (ICD)-11 revision. Allergy 2017; 72:820–826.
Tanno LK, Chalmers R, Bierrenbach AL, et al., Joint Allergy Academies. Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases-11. J Allergy Clin Immunol 2019; 144:627–633.
Demoly P, Tanno L. Le modèle de l’anaphylaxie: une nouvelle version de la Classification internationale des maladies de l’Organisation mondiale de la santé pour 2019 [The model of anaphylaxis: a new version of the International Classification of Diseases from the World Health Organization]. Bull Acad Natle Med 2020; 1:97–101.
Chen RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994; 12:542–550.
Halsey NA. The science of evaluation of adverse events associated with vaccination. Semin Pediatr Infect Dis 2002; 13:205–214.
French National Agency for the Safety of Medicines and Health Products website. Available: at: https://ansm.sante.fr/uploads/2021/04/16/20210412-vaccins-covid-19-fiche-de-synhtese-vf.pdf . [Assessed April 2021]
Dreskin SC, Halsey NA, Kelso JM, et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J 2016; 9:32.
Somiya M, Mine S, Yasukawa K, et al. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines. Vaccine 2021; 39:3313–3314.
Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy 2016; 46:907–922.
Selvaraj G, Kaliamurthi S, Peslherbe GH, Wei DQ. Are the allergic reactions of COVID-19 vaccines caused by mRNA constructs or nanocarriers? Immunol Insights Interdiscip Sci 2021; 13:344–347.
Troelnikov A, Perkins G, Yuson C, et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in PEG allergic patients. J Allergy Clin Immunol 2021; 148:91–95.
WHO website. COVID-19 vaccines: safety surveillance manual. Available at: https://apps.who.int/iris/bitstream/handle/10665/338400/9789240018280-eng.pdf?sequence=1&isAllowed=y . [Assessed May 2021]
Clark T. Presentation to ACI COVID-19 vaccines work group December 19 2020 meeting. 2020. Anaphylaxis following m-RNA COVID-19 vaccine receipt. Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/slides-12-19/05-COVID-Clark-508.pdf .
COVID-19 vaccine safety update. 27 January 2021. Available at: https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-28-january-2021_en.pdf . [Assessed May 2021]
Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA 2021; 325:780–781.
Blumenthal KG, Robinson LB, Camargo CA Jr, et al. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA 2021; e213976.
Povsic TJ, Lawrence MG, Lincoff AM, et al. Preexisting anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J Allergy Clin Immunol 2016; 138:1712–1715.
Yang Q, Jacobs TM, McCallen JD, et al. Analysis of preexisting IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal Chem 2016; 88:11804–11812.
Chen W, Mempel M, Schober W, et al. Gender difference, sex hormones, and immediate type hypersensitivity reactions. Allergy 2008; 63:1418–1427.
Bianchi I, Lleo A, Gershwin ME, Invernizzi P. The X chromosome and immune associated genes. J Autoimmun 2012; 38:J187–J192.
Salvati L, Vitiello G, Parronchi P. Gender differences in anaphylaxis. Curr Opin Allergy Clin Immunol 2019; 19:417–424.
Lieberman P. Catamenial anaphylaxis. J Allergy Clin Immunol Pract 2014; 2:358–359.
Hox V, Desai A, Bandara G, et al. Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production. J Allergy Clin Immunol 2015; 135:729729.e5-736.e5.
Rama TA, Moreira A, Castells M. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis. J Allergy Clin Immunol 2021; 147:877–878.
Bonadonna P, Brockow K, Niedoszytko M, et al. COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). J Allergy Clin Immunol Pract 2021; 9:2139–2144.
Sampath V, Rabinowitz G, Shah M, et al. Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives. Allergy 2021; 76:1640–1660.